Alkahest, Inc.

Edison Pharmaceuticals, Inc.

Bioelectron Technology Corporation

Conopco, Inc.

Ptc Therapeutics, Inc.

Unilever, N.v.

Unilever Plc, a Company Registered in England and Wales Under Company No. 41424 of

Viktoria Kheifets

Benson Lu

Guy M Miller

Andrew W Hinman

Ian Gallager

Marian Castro

Annette Tennstaedt

William Dvorak Shrader

Dana Davis

Methods and compositions for treating aging-related diseases as well as muscle recovery, prevention of muscle degeneration, and maintenance of muscle are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

Blood plasma fractions for use in muscle regeneration

Methods and compositions for treating aging-related diseases as well as liver regeneration, prevention of liver degeneration, and maintenance of liver are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

Blood plasma fractions for use in liver regeneration

Provided herein are methods of inducing liver regeneration in a subject diagnosed with a liver disorder. The method comprises administering a Plasma Protein Fraction (PPF) to the subject. In certain embodiments, the PPF comprises between 83% and 95% albumin in relation to total proteins. The PPF can be produced from plasma obtained from young individuals, for example, humans 40 years of age or younger.

Methods of inducing liver regeneration by administering a plasma protein fraction

The disclosure pertains to methods of treating pain. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to treat pain.

Methods of treating a subject for pain

Method of treating liver failure with plasma fraction IV-4

The disclosure pertains to methods of improving wound healing. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to treat a wound.

Methods of improving wound healing

The disclosure pertains to methods for improving postoperative recovery. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to improve or accelerate postoperative recovery.

Methods of improving or accelerating postoperative recovery

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Treatment of pervasive developmental disorders with redox-active therapeutics

Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

Resorcinol compounds for dermatological use

Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: Rand Rare independently hydrogen, (C-C)alkyl or &#x2014;O(C-C)alkyl; or Rand Rtogether represent &#x2014;CH&#x2550;CH&#x2014;CH&#x2550;CH&#x2014;; Ris (C1-C6)alkyl; X is &#x2014;CH&#x2550;CH&#x2014; or &#x2014;C&#x2261;C&#x2014;; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the &#x2014;X&#x2014;(CH)&#x2014; group; Y is &#x2014;OR, &#x2014;CN, &#x2014;C(&#x2550;O)OR, &#x2014;C(&#x2550;O)R, or &#x2014;C(&#x2550;O)N(R); Rand Rare independently selected from the group consisting of hydrogen, &#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;(C-C)haloalkyl, &#x2014;C(&#x2550;O)&#x2014;NH(C-C)alkyl, &#x2014;C(&#x2550;O)&#x2014;N((C-C)alkyl), &#x2014;C(&#x2550;O)&#x2014;NH, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of &#x2014;(C-C)alkyl, &#x2014;O&#x2014;(C-C)alkyl, &#x2014;(C-C)haloalkyl, and halo; each Ris independently hydrogen or &#x2014;(C-C)alkyl; and M is &#x2014;H, &#x2014;C(O)&#x2014;Ror &#x2014;C(O)O&#x2014;R, wherein Ris &#x2014;(C-C)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof. 

Benzoquinone derivatives for treating oxidative stress disorders

Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD&#x2014;not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.

Growing community of inventors

Mountain View, CA, United States of America

Viktoria Kheifets